

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended **September 30, 2015**

Commission File Number **001-31932**

CATASYS, INC.

(Exact name of registrant as specified in its charter)

Delaware

(State or other jurisdiction of incorporation or organization)

88-0464853

(I.R.S. Employer Identification No.)

11601 Wilshire Boulevard, Suite 1100, Los Angeles, California 90025

(Address of principal executive offices, including zip code)

(310) 444-4300

(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Website, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer or a smaller reporting company. See definitions of "accelerated filer," "large accelerated filer," and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer Accelerated filer Non-accelerated filer Smaller reporting company

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

Yes No

As of November 12, 2015, there were 55,007,761 shares of the registrant's common stock, \$0.0001 par value per share, outstanding.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION	3
ITEM 1. Financial Statements	3
Condensed Consolidated Balance Sheets as of September 30, 2015 (unaudited) and December 31, 2014	3
Condensed Consolidated Statements of Operations for the Three and Nine Months Ended September 30, 2015 and 2014 (unaudited)	4
Condensed Consolidated Statements of Cash Flows for the Nine Months Ended September 30, 2015 and 2014 (unaudited)	5
Notes to Condensed Consolidated Financial Statements	6
ITEM 2. Management's Discussion and Analysis of Financial Condition and Results of Operations	16
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk	23
ITEM 4. Controls and Procedures	23
PART II – OTHER INFORMATION	24
ITEM 1. Legal Proceedings	24
ITEM 1A. Risk Factors	24
ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds	24
ITEM 3. Defaults Upon Senior Securities	24
ITEM 4. Mine Safety Disclosures	24
ITEM 5. Other Information	24
ITEM 6. Exhibits	24

In this report, except as otherwise stated or the context otherwise requires, the terms “we,” “us” or “our” refer to Catasys, Inc. and our wholly-owned subsidiaries. Our common stock, par value \$0.0001 per share, is referred to as “common stock.”

PART I - FINANCIAL INFORMATION

Item 1. Financial Statements

**CATASYS, INC. AND SUBSIDIARIES
 CONDENSED CONSOLIDATED BALANCE SHEETS**

(In thousands, except for number of shares)	September 30, 2015 (unaudited)	December 31, 2014
ASSETS		
Current assets		
Cash and cash equivalents	\$ 225	\$ 708
Receivables, net of allowance for doubtful accounts of \$9 and \$0, respectively	418	189
Receivables from related party	-	300
Prepays and other current assets	599	313
Total current assets	1,242	1,510
Long-term assets		
Property and equipment, net of accumulated depreciation of \$1,827 and \$2,002, respectively	297	354
Intangible assets, net of accumulated amortization of \$0 and \$418, respectively	-	101
Deposits and other assets	387	387
Total Assets	<u>\$ 1,926</u>	<u>\$ 2,352</u>
LIABILITIES AND STOCKHOLDERS' DEFICIT		
Current liabilities		
Accounts payable	\$ 693	\$ 341
Accrued compensation and benefits	1,514	1,392
Deferred revenue	1,554	354
Other accrued liabilities	715	614
Short term convertible debt, related party, net of discount \$1,608 and \$0, respectively	2,008	-
Short term derivative liability	6,046	-
Warrant liabilities	-	259
Total current liabilities	12,530	2,960
Long-term liabilities		
Deferred rent and other long-term liabilities	216	267
Capital leases	17	23
Warrant liabilities	1,258	40,326
Total Liabilities	14,021	43,576
Stockholders' deficit		
Preferred stock, \$0.0001 par value; 50,000,000 shares authorized; no shares issued and outstanding	-	-
Common stock, \$0.0001 par value; 500,000,000 shares authorized; 48,141,094 and 25,244,485 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	5	3
Additional paid-in-capital	250,722	213,333
Accumulated deficit	(262,822)	(254,560)
Total Stockholders' Deficit	(12,095)	(41,224)
Total Liabilities and Stockholders' Deficit	<u>\$ 1,926</u>	<u>\$ 2,352</u>

See accompanying notes to the financial statements.

CATASYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)

(In thousands, except per share amounts)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Revenues				
Healthcare services revenues	\$ 538	\$ 370	\$ 1,443	\$ 881
Operating expenses				
Cost of healthcare services	720	346	1,655	878
General and administrative	1,968	1,596	7,124	4,642
Depreciation and amortization	30	30	94	82
Total operating expenses	2,718	1,972	8,873	5,602
Loss from operations	(2,180)	(1,602)	(7,430)	(4,721)
Other Income	20	-	41	1,194
Interest expense	(1,209)	(2)	(2,321)	(2,776)
Loss on disposal of intangible assets	(88)	-	(88)	-
Loss on exchange of warrants	-	-	(4,410)	-
Change in fair value of warrant liability	1,007	1,397	10,915	(18,995)
Change in fair value of derivative liability	(5,027)	-	(5,027)	-
Loss from continuing operations before provision for income taxes	(7,477)	(207)	(8,320)	(25,298)
Provision for income taxes	3	3	7	7
Loss from continuing operations	\$ (7,480)	\$ (210)	\$ (8,327)	\$ (25,305)
Loss from discontinued operations, net of income taxes	\$ -	\$ -	\$ -	\$ (213)
Net Loss	\$ (7,480)	\$ (210)	\$ (8,327)	\$ (25,518)
Basic and diluted net loss from continuing operations per share:				
	\$ (0.16)	\$ (0.01)	\$ (0.23)	\$ (1.17)
Basic weighted number of shares outstanding	47,638	23,513	36,181	21,569
Basic and diluted net loss from discontinued operations per share:				
	\$ 0.00	\$ 0.00	\$ 0.00	\$ (0.01)
Diluted weighted number of shares outstanding	47,638	23,513	36,181	21,569

See accompanying notes to the financial statements.

CATASYS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(unaudited)

(In thousands)	Nine Months Ended	
	September 30,	
	2015	2014
Operating activities:		
Net loss	\$ (8,327)	\$ (25,518)
Adjustments to reconcile net loss to net cash used in operating activities:		
Loss from discontinued operations	\$ -	\$ 213
Depreciation and amortization	94	82
Loss on disposal of intangible assets	88	-
Amortization of debt discount and issuance costs included in interest expense	2,166	2,771
Warrants issued for services	112	-
Provision for doubtful accounts	65	-
Write-off of accrued liabilities	-	(1,194)
Deferred rent	(58)	122
Share-based compensation expense	1,223	39
Common stock issued for consulting services	172	-
Transaction Costs	-	350
Fair value adjustment on warrant liability	(10,915)	18,995
Loss on exchange of warrants	4,410	-
Fair value adjustment on derivative liability	5,027	-
Changes in current assets and liabilities:		
Receivables	71	1
Prepays and other current assets	136	201
Deferred revenue	1,200	454
Accounts payable and other accrued liabilities	664	48
Net cash used by operating activities of continuing operations	\$ (3,872)	\$ (3,436)
Net cash used by operating activities of discontinued operations	\$ -	\$ (215)
Net cash used by operating activities	\$ (3,872)	\$ (3,651)
Investing activities:		
Purchases of property and equipment	\$ (18)	\$ (64)
Deposits and other assets	(87)	53
Net cash used by investing activities	\$ (105)	\$ (11)
Financing activities:		
Proceeds from the issuance of common stock and warrants	\$ 463	\$ 4,000
Proceeds from the exercise of warrants	-	77
Proceeds from the issuance of convertible debt, related party	5,910	-
Payments on convertible debenture	(2,681)	-
Transaction Costs	(185)	-
Capital lease obligations	(13)	(19)
Net cash provided by financing activities	\$ 3,494	\$ 4,058
Net increase (decrease) in cash and cash equivalents	\$ (483)	\$ 396
Cash and cash equivalents at beginning of period	708	1,136
Cash and cash equivalents at end of period	\$ 225	\$ 1,532
Supplemental disclosure of cash paid		
Interest	\$ 190	\$ -
Income taxes	\$ 40	\$ 11
Supplemental disclosure of non-cash activity		
Common stock issued for exercise of warrants	\$ -	\$ 166
Property and equipment acquired through capital leases and other financing	\$ 7	\$ 16

See accompanying notes to the financial statements.

Catasys, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(unaudited)

Note 1. Basis of Consolidation, Presentation and Going Concern

The accompanying unaudited condensed consolidated financial statements for Catasys, Inc. and its subsidiaries have been prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP") and instructions to Form 10-Q and, therefore, do not include all disclosures necessary for a complete presentation of financial position, results of operations, and cash flows in conformity with U.S. GAAP. In our opinion, all adjustments, consisting of normal recurring adjustments, considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of the results that may be expected for the entire fiscal year. The accompanying financial information should be read in conjunction with the financial statements and the notes thereto included in our most recent Annual Report on Form 10-K for the year-ended December 31, 2014, from which the balance sheets, as of December 31, 2014, have been derived.

Our financial statements have been prepared on the basis that we will continue as a going concern. At September 30, 2015, cash and cash equivalents was \$225,000 and we had a working capital deficit of approximately \$11.3 million. In October 2015, we entered into Stock Purchase Agreements with Acuitas Group Holdings, LLC ("Acuitas"), 100% owned by Terren S. Peizer, our Chairman and Chief Executive Officer, Shamus, LLC ("Shamus"), a Company owned by David E. Smith, a member of our board of directors, and Steve Gorlin, a member of our board of directors, pursuant to which we received gross proceeds of \$2.0 million in exchange for approximately 6.7 million shares of our common stock. We have incurred significant operating losses and negative cash flows from operations since our inception. During the nine months ended September 30, 2015, our cash used in operating activities of continuing operations was \$3.9 million. We anticipate that we could continue to incur negative cash flows and net losses for the next twelve months. The financial statements do not include any adjustments relating to the recoverability of the carrying amount of the recorded assets or the amount of liabilities that might result from the outcome of this uncertainty. As of September 30, 2015, these conditions raised substantial doubt as to our ability to continue as a going concern. We expect our current cash resources to cover expenses through the first quarter of 2016; however delays in cash collections, revenue, or unforeseen expenditures could negatively impact our estimate. We are in need of additional capital, however, there is no assurance that additional capital can be timely raised in an amount which is sufficient for us or on terms favorable to us and our stockholders, if at all. If we do not obtain additional capital, there is a significant doubt as to whether we can continue to operate as a going concern and we will need to curtail or cease operations or seek bankruptcy relief. If we discontinue operations, we may not have sufficient funds to pay any amounts to our stockholders.

Our ability to fund our ongoing operations and continue as a going concern is dependent on increasing the number of members that are eligible for our programs by signing new contracts and generating fees from existing and new contracts for our managed care programs and the success of management's plans to increase revenue and continue to control expenses. We currently operate our *OnTrak* for substance dependence program in Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, Oklahoma, West Virginia and Wisconsin, and our *OnTrak* for anxiety program in Kansas. During the third quarter of 2015, we launched our programs in Illinois and Missouri and signed an agreement with one of our national health plan customers to expand our program to Pennsylvania. In addition, we recently received approval from one of our national health plan customers to expand our program to its Medicare members in several states beginning in the fourth quarter under our national contract, which was signed earlier this year. We have generated fees from our launched programs and expect to increase enrollment and fees throughout 2015. However, there can be no assurance that we will generate such fees or that new programs will launch as we expect.

We have discontinued our license and management fee segment. The operations were shut down effective April 1, 2014 and all of the assets were absorbed by the Company.

Note 2. Summary of Significant Accounting Policies

Revenue Recognition

Our Catasys contracts are generally designed to provide cash fees to us on a monthly basis based on enrolled members. To the extent our contracts may include a minimum performance guarantee, we reserve a portion of the monthly fees that may be at risk until the performance measurement period is completed. To the extent we receive case rates or other fees in advance that are not subject to the performance guarantees, we recognize the case rate ratably over the twelve months of our program.

Cost of Services

Cost of healthcare services consists primarily of salaries related to our care coaches, community care coordinators, healthcare provider claims payments, and fees charged by our third party administrators for processing these claims. Healthcare services cost of services is recognized in the period in which an eligible member receives services. We contract with doctors and licensed behavioral healthcare professionals, on a fee-for-services basis. We determine that a member has received services when we receive a claim or, in the absence of a claim, by utilizing member data recorded in the OnTrakTM database within the contracted timeframe, with all required billing elements correctly completed by the service provider.

Cash Equivalents and Concentration of Credit Risk

We consider all highly liquid investments with an original maturity of three months or less to be cash equivalents. Financial instruments that potentially subject us to a concentration of credit risk consist of cash and cash equivalents, and accounts receivable. Cash is deposited with what we believe are highly credited, quality financial institutions. The deposited cash may exceed Federal Deposit Insurance Corporation ("FDIC") insured limits. As of September 30, 2015, cash and cash equivalents exceeding federally insured limits totaled \$88,000.

For the nine months ended September 30, 2015, three customers accounted for approximately 97% of revenues and three customers accounted for approximately 88% of accounts receivable.

Basic and Diluted Income (Loss) per Share

Basic income (loss) per share is computed by dividing the net income (loss) to common stockholders for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing the net income (loss) for the period by the weighted average number of common shares and dilutive common equivalent shares outstanding during the period.

Common equivalent shares, consisting of 3,443,612 and 22,112,493 common shares for the nine months ended September 30, 2015 and 2014, respectively, issuable upon the exercise of stock options and warrants have been excluded from the diluted earnings per share calculation as their effect is anti-dilutive.

Share-Based Compensation

Our 2010 Stock Incentive Plan as amended (the "Plan"), provides for the issuance of up to 1,825,000 shares of our common stock. Incentive stock options (ISOs) under Section 422A of the Internal Revenue Code and non-qualified options (NSOs) are authorized under the Plan. We have granted stock options to executive officers, employees, members of our board of directors, and certain outside consultants. The terms and conditions upon which options become exercisable vary among grants, but option rights expire no later than ten years from the date of grant and employee and board of director awards generally vest over three to five years. At September 30, 2015, we had 1,567,975 vested and unvested stock options outstanding and 199,788 shares available for future awards under the Plan.

Share-based compensation expense attributable to continuing operations were \$186,000 and \$1.2 million for the three and nine months ended September 30, 2015, compared with \$13,000 and \$39,000 for the same periods in 2014, respectively.

Stock Options – Employees and Directors

We measure and recognize compensation expense for all share-based payment awards made to employees and directors based on estimated fair values on the date of grant. We estimate the fair value of share-based payment awards using the Black-Scholes option-pricing model. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in the condensed consolidated statements of operations.

Share-based compensation expense recognized for employees and directors for the three and nine months ended September 30, 2015 was \$186,000 and \$1.2 million, compared with \$11,000 and \$34,000, for the same periods in 2014, respectively.

For share-based awards issued to employees and directors, share-based compensation is attributed to expense using the straight-line single option method. Share-based compensation expense recognized in our condensed consolidated statements of operations for the three and nine months ended September 30, 2015 and 2014 is based on awards ultimately expected to vest, reduced for estimated forfeitures. Accounting rules for stock options require forfeitures to be estimated at the time of grant and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

There were 0 and 1,050,000 options granted to directors during the three and nine months ended September 30, 2015, and 0 and 250,000 options granted to employees during the same period of 2015, respectively. No options were granted to employees and directors during the same period in 2014 under the Plan. Employee and director stock option activity for the three and nine months ended September 30, 2015 are as follows:

	Shares	Weighted Avg. Exercise Price
Balance December 31, 2014	378,000	\$ 19.59
Granted	1,300,000	\$ 2.20
Cancelled	(1,000)	\$ 45.20
Balance March 31, 2015	1,677,000	\$ 6.22
Granted	-	\$ -
Cancelled	-	\$ 112.00
Balance June 30, 2015	1,677,000	\$ 6.06
Granted	-	\$ -
Cancelled	(109,000)	\$ 2.98
Balance September 30, 2015	1,568,000	\$ 6.27

The expected volatility assumptions have been based on the historical and expected volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected option term for the three and nine months ended September 30, 2015 and 2014, reflects the application of the simplified method prescribed in SEC Staff Accounting Bulletin ("SAB") No. 107 (as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

As of September 30, 2015, there was \$1.2 million of total unrecognized compensation cost related to non-vested share-based compensation arrangements granted under the Plan. That cost is expected to be recognized over a weighted-average period of approximately 2.01 years.

Stock Options and Warrants – Non-employees

We account for the issuance of options and warrants for services from non-employees by estimating the fair value of warrants issued using the Black-Scholes pricing model. This model's calculations include the option or warrant exercise price, the market price of shares on grant date, the weighted average risk-free interest rate, the expected life of the option or warrant, and the expected volatility of our stock and the expected dividends.

For options and warrants issued as compensation to non-employees for services that are fully vested and non-forfeitable at the time of issuance, the estimated value is recorded in equity and expensed when the services are performed and benefit is received. For unvested shares, the change in fair value during the period is recognized in expense using the graded vesting method.

There were no options issued to non-employees for the three and nine months ended September 30, 2015 and 2014. Share-based compensation expense relating to stock options and warrants recognized for non-employees was \$0 and \$3,000 for the three and nine months ended September 30, 2015 and \$2,000 and \$5,000 for the three and nine months ended September 30, 2014, respectively.

Non-employee stock option activity for the three and nine months ended September 30, 2015, are as follows:

	Shares	Weighted Avg. Exercise Price
Balance December 31, 2014	21,000	\$ 28.40
Granted	-	\$ -
Cancelled	-	\$ -
Balance March 31, 2015	21,000	\$ 28.40
Granted	-	\$ -
Cancelled	(21,000)	\$ 28.40
Balance June 30, 2015	-	\$ -
Granted	-	\$ -
Cancelled	-	\$ -
Balance September 30, 2015	-	\$ -

Common Stock

In September 2015, we entered into a Stock Purchase Agreement with Acuitas, relating to the sale and issuance of approximately 1.5 million shares of common stock for gross proceeds of \$463,000 (the "September Offering").

In May 2015, we entered into Warrant Exchange Agreements (the "Exchange Agreements") whereby 21,277,220 warrants, at an exercise price of \$0.58 per shares, issued by the Company between December 2011 and May 2014, were exchanged for 21,277,220 shares of common stock to eliminate the liability associated with these warrants.

There were 0 and 76,000 shares of common stock issued for investor relations or consulting services during the three and nine months ended September 30, 2015 compared to 55,000 and 255,000 shares issued for the same periods in 2014, respectively. Generally, the costs associated with shares issued for services are being amortized to the related expense on a straight-line basis over the related service periods.

Income Taxes

We have recorded a full valuation allowance against our otherwise recognizable deferred tax assets as of September 30, 2015. As such, we have not recorded a provision for income tax for the period ended September 30, 2015. We utilize the liability method of accounting for income taxes as set forth in ASC 740, Income Taxes. Under the liability method, deferred taxes are determined based on the temporary differences between the financial statement and tax basis of assets and liabilities using tax rates expected to be in effect during the years in which the basis differences reverse. A valuation allowance is recorded when it is more likely than not that some of the deferred tax assets will not be realized. In determining the need for valuation allowances, we consider projected future taxable income and the availability of tax planning strategies. After evaluating all positive and negative historical and perspective evidences, management has determined it is more likely than not that our deferred tax assets will not be realized.

We assess our income tax positions and record tax benefits for all years subject to examination based upon our evaluation of the facts, circumstances and information available at the reporting date. For those tax positions where there is greater than 50% likelihood that a tax benefit will be sustained, we have recorded the largest amount of tax benefit that may potentially be realized upon ultimate settlement with a taxing authority that has full knowledge of all relevant information. For those income tax positions where there is less than 50% likelihood that a tax benefit will be sustained, no tax benefit has been recognized in the financial statements. Based on management's assessment of the facts, circumstances and information available, management has determined that all of the tax benefits for the period ended September 30, 2015 should be realized.

Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities recorded at fair value in the condensed consolidated balance sheets are categorized based upon the level of judgment associated with the inputs used to measure fair value. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level I) and the lowest priority to unobservable inputs (Level III). The three levels of the fair value hierarchy are described below:

Level Input:	Input Definition:
Level I	Inputs are unadjusted, quoted prices for identical assets or liabilities in active markets at the measurement date.
Level II	Inputs, other than quoted prices included in Level I, that are observable for the asset or liability through corroboration with market data at the measurement date.
Level III	Unobservable inputs that reflect management's best estimate of what market participants would use in pricing the asset or liability at the measurement date.

The following table summarizes fair value measurements by level at September 30, 2015 for assets and liabilities measured at fair value:

	2015			
<i>(In thousands)</i>	Level I	Level II	Level III	Total
Certificates of deposit	\$ 122	\$ -	\$ -	\$ 122
Total assets	\$ 122	\$ -	\$ -	\$ 122
Warrant liabilities	\$ -	\$ -	\$ 1,258	\$ 1,258
Derivative liabilities	-	-	\$ 6,046	\$ 6,046
Total liabilities	\$ -	\$ -	\$ 7,304	\$ 7,304

Financial instruments classified as Level III in the fair value hierarchy as of September 30, 2015, represent our liabilities measured at market value on a recurring basis which include warrant liabilities and derivative liabilities resulting from recent debt and equity financings. In accordance with current accounting rules, the warrant liabilities and derivative liabilities are being marked-to-market each quarter-end until they are completely settled. The warrants and derivative liabilities are valued using the Black-Scholes option-pricing model, using both observable and unobservable inputs and assumptions consistent with those used in our estimate of fair value of employee stock options. See *Warrant Liabilities* below.

The following table summarizes our fair value measurements using significant Level III inputs, and changes therein, for the three and nine months ended September 30, 2015:

<i>(In thousands)</i>	Level III Warrant Liabilities	Level III Derivative Liabilities
Balance as of December 31, 2014	\$ 40,585	\$ -
Issuance of warrants or derivative	-	-
Change in fair value	(2,474)	-
Balance as of March 31, 2015	\$ 38,111	\$ -
Issuance of warrants or derivative	1,419	-
Exchange of warrants	(31,124)	-
Change in fair value	(7,434)	-
Balance as of June 30, 2015	\$ 972	\$ -
Issuance of warrants or derivative	1,293	1,019
Change in fair value	(1,007)	5,027
Balance as of September 30, 2015	\$ 1,258	\$ 6,046

Intangible Assets

As of September 30, 2015, there were no intangible assets subject to amortization.

<i>(In thousands)</i>	Gross Carrying Amount	Accumulated Amortization	Net Balance	Amortization Period (in years)
Intellectual property	\$ -	\$ -	\$ -	0

During the three and nine months ended September 30, 2015, we did not acquire any new intangible assets and at September 30, 2015, we determined that the intangible assets had no value and were written off in full.

Property and Equipment

Property and equipment are stated at cost, less accumulated depreciation. Additions and improvements to property and equipment are capitalized at cost. Expenditures for maintenance and repairs are charged to expense as incurred. Depreciation is computed using the straight-line method over the estimated useful lives of the related assets, which range from two to seven years for furniture and equipment. Leasehold improvements are amortized over the lesser of the estimated useful lives of the assets or the related lease term, which is typically five to seven years.

Warrant Liabilities

In July 2015, we entered into \$3.55 million 12% Original Issue Discount Convertible Debenture due January 18, 2016 (the "July 2015 Convertible Debenture") with Acuitas and five-year warrants to purchase 935,008 shares of our common stock, at an exercise price of \$1.90 per share, subject to adjustment, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be (the "July 2015 Warrants").

The conversion price of the July 2015 Convertible Debenture is \$1.90 per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be. The July 2015 Convertible Debentures are unsecured, bear interest at a rate of 12% per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and are subject to mandatory prepayment upon the consummation of certain future financings.

The conversion price of the July 2015 Convertible Debenture and the July 2015 Warrants were subsequently adjusted to \$0.30 per share based upon the September Offering.

In May 2015, we entered into the Exchange Agreements whereby 21,277,220 warrants, at an exercise price of \$0.58 per shares, issued by the Company between December 2011 and May 2014, were exchanged for 21,277,220 shares of common stock (the "Warrant Exchange"). We recognized a \$0 and \$4.4 million loss related to the Warrant Exchange for the three and nine months ended September 30, 2015, respectively.

In conjunction with the Securities Purchase Agreement entered in April 2015, the Company issued five year warrants to purchase an aggregate of 530,303 shares of our common stock, at an exercise price of \$2.00 per share, subject to adjustment, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be (the "April 2015 Warrants"). The exercise price of the April 2015 Warrants was subsequently adjusted to \$0.30 per share based upon the September Offering.

We have issued warrants to purchase common stock in November 2010, December 2011, February 2012, April 2015, and July 2015. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

For the three and nine months ended September 30, 2015 and 2014, we recognized a gain of \$1.0 million and \$10.9 million, respectively, compared with a gain of \$1.4 million and a loss of \$19.0 million for the same periods in 2014, respectively, related to the revaluation of our warrant liabilities.

Derivative Liabilities

In July 2015, we entered into the July 2015 Convertible Debenture. The derivative liability associated with the July 2015 Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions:

	<u>September 30, 2015</u>
Expected volatility	146.52%
Risk-free interest rate	0.10%
Weighted average expected lives in years	0.30
Expected dividend	0%

The expected volatility assumption for 2015 was based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected lives in years for 2015 reflect the application of the simplified method set out in Security and Exchange Commission (SEC) Staff Accounting Bulletin (SAB) 107 (and as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. We use historical data to estimate the rate of forfeitures assumption for awards granted to employees.

For the three and nine months ended September 30, 2015 and 2014, we recognized a loss of \$5.0 million, related to the revaluation of our derivative liability.

Recently Issued or Newly Adopted Accounting Standards

In February 2015, the FASB issued Accounting Standards Update ("ASU") 2015-02, *Consolidation (Topic 810): Amendments to the Consolidation Analysis* ("ASU 2015-02"). ASU 2015-02 modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoptions. Early adoption is permitted. We are currently evaluating the potential impact of this standard on our consolidated financial statements, as well as the available transition methods.

In August 2014, the FASB issued FASB ASU 2014-15, *Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern*, (“ASU 2014-15”). ASU 2014-15 changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for periods beginning after December 15, 2016. The adoption of ASU 2013-15 will not have a material effect on our consolidated financial position or results of operations.

Note 3. Discontinued Operations

We have discontinued our license and management fees segment. The operations of this segment were shut down effective April 1, 2014, and all of the assets were absorbed by the healthcare services segment. The revenue and expenses of discontinued operations for the three and nine months ended September 30, 2015 and 2014 are as follows:

(in thousands)	Three months ended September 30, (unaudited)		Nine months ended September 30, (unaudited)	
	2015	2014	2015	2014
Revenue	\$ -	\$ -	\$ -	\$ 25
Expenses				
Cost of license and management services	\$ -	\$ -	\$ -	\$ 55
General and administrative expenses				
Salaries and benefits	-	-	-	96
Other expenses	-	-	-	83
Depreciation and amortization	-	-	-	4
Total expenses	\$ -	\$ -	\$ -	\$ 238
Gain (loss) from discontinued operations	\$ -	\$ -	\$ -	\$ (213)

There was no carrying amount of the assets and liabilities of discontinued operations as of September 30, 2015 and December 31, 2014.

Note 4. Related Party Disclosure

In December 2014, we entered into securities purchase agreement with several investors including Steve Gorlin, an affiliate of the Company, related to the sale and issuance of common stock. Mr. Gorlin received approximately 150,000 shares of common stock at a price of \$2.00 per share, for gross proceeds of approximately \$300,000. Such proceeds were received subsequent to 2014.

Terren Peizer, Chairman and Chief Executive Officer, transferred his securities ownership in Catasys to Acuitas from Crede Capital Group, LLC. Mr. Peizer owns 100% of both entities.

Acuitas participated in our January 2014, May 2014, December 2014, July 2015 and September 2015 offerings. Acuitas received approximately 5,276,266 shares of our common stock and warrants to purchase an aggregate 935,008 shares of common stock, at a price of \$0.30 per share, for gross proceeds to us of approximately \$6.3 million.

In addition, we have a \$3.6 Convertible Debenture outstanding with Acuitas, which includes \$81,000 in interest as of September 30, 2015. We also have accounts payable outstanding with Mr. Peizer for travel and expenses of \$125,000 as of September 30, 2015.

Shamus participated in our May 2014 offering. Shamus received approximately 344,828 shares of our common stock and warrants to purchase an aggregate 344,828 shares of common stock, at a price of \$0.58 per share, for gross proceeds to us of approximately \$200,000. These warrants were subsequently converted to 344,828 shares of common stock as part of the Warrant Exchange in May 2015.

Note 5. Short-term Debt

In April 2015, we entered into a Securities Purchase Agreement with several institutional accredited investors, pursuant to which we received aggregate gross proceeds of \$2.0 million from the investors for the sale of approximately \$2.12 million principal amount of 12% Original Issue Discount Convertible Debentures due January 18, 2016 (the "April 2015 Bridge Notes") and the April 2015 Warrants. The closing of the April 2015 Bridge Notes transaction occurred on April 17, 2015. We received aggregate net proceeds of \$1,815,000. We used \$560,000 of the net proceeds to repay our outstanding indebtedness due to Crede incurred by way of short term, interest free loans in the first and second quarters of 2015.

The conversion price of the April 2015 Bridge Notes and the exercise price of the April 2015 Warrants was \$2.00 per share, subject to adjustment, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be. The April 2015 Bridge Notes were unsecured, bear interest at a rate of 12% per annum payable quarterly in cash or shares of common stock, subject to certain conditions, at our option, and were subject to mandatory prepayment upon the consummation of certain future financings. The exercise price of the April 2015 Warrants was subsequently adjusted to \$0.30 per share based upon the September Offering.

In July 2015, we entered into a promissory note with Acuitas, pursuant to which we received gross proceeds of \$3.35 million for the sale of \$3.35 million in principal amount (the "Promissory Note"). The Promissory Note was due on August 21, 2015, and carried an interest rate on any unpaid principal amount of 8% per annum until the maturity date, after which the interest rate would increase to 12% per annum. We used approximately \$2.2 million of the net proceeds of this transaction to redeem the April 2015 Bridge Notes. Following the redemption, all of the April 2015 Bridge Notes were extinguished.

In July 2015, we issued the July 2015 Convertible Debenture and the July 2015 Warrants for the Promissory Note.

The conversion price of the July 2015 Convertible Debenture was \$1.90 per share, subject to adjustments, including for issuances of common stock and common stock equivalents below the then current conversion or exercise price, as the case may be. The July 2015 Convertible Debentures are unsecured, bear interest at a rate of 12% per annum payable in cash or shares of common stock, subject to certain conditions, at our option, and are subject to mandatory prepayment upon the consummation of certain future financings.

The conversion price of the July 2015 Convertible Debenture and the exercise price of the July 2015 Warrants were subsequently adjusted to \$0.30 per share based upon the September Offering.

Note 6. Other Income/Write-off of Liabilities

For the three and nine months ended September 30, 2014, the statute on a contract, initially entered into in 2005 and amended and breached in 2010 expired in accordance with Section 337 of the California Code of Civil Procedures. Accordingly, we wrote off all balances included in accounts payable and accrued liabilities on our books relating to this contract which amounted to approximately \$1.2 million.

Note 7. Subsequent Event

In October 2015, we entered into Stock Purchase Agreements (the "Purchase Agreements") with each of Acuitas, Shamus, and Steve Gorlin, pursuant to which the Company received gross proceeds of \$2.0 million for the sale of approximately 6.7 million shares of the Company's common stock, at a purchase price of \$0.30 per share.

In addition, we entered into entered into an amendment to the 12% Original Issue Discount Convertible Debenture dated July 30, 2015 with Acuitas to extend the maturity date of the July 2015 Convertible Debenture from January 18, 2016 to January 18, 2017 and extended the date by which we must consummate a qualified public offering or pay a penalty from December 31, 2015 to June 30, 2016.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements including the related notes, and the other financial information included elsewhere in this report.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING INFORMATION

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to the financial condition, results of operations, business strategies, operating efficiencies or synergies, competitive positions, growth opportunities for existing products, plans and objectives of management, markets for our stock and other matters. Statements in this report that are not historical facts are hereby identified as “forward-looking statements” for the purpose of the safe harbor provided by Section 21E of the Exchange Act of 1934 and Section 27A of the Securities Act of 1933. Such forward-looking statements, including, without limitation, those relating to the future business prospects, our revenue and income, wherever they occur, are necessarily estimates reflecting the best judgment of our senior management as of the date on which they were made, or if no date is stated, as of the date of this report. These forward-looking statements are subject to risks, uncertainties and assumptions, including those described in the “Risk Factors” in Item 1A of Part I of our most recent Annual Report on Form 10-K (“Form 10-K”) for the fiscal year ended December 31, 2014 and other reports we filed with the Securities and Exchange Commission (“SEC”), that may affect the operations, performance, development and results of our business. Because the factors discussed in this report could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any such forward-looking statements. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. We assume no obligation and do not intend to update these forward looking statements, except as required by law.

OVERVIEW

General

We provide specialized healthcare management services to health plans and other third party payors through our *OnTrak* program. Our *OnTrak* program is designed to improve member health and at the same time lower costs to the insurer for underserved populations where behavioral health conditions are causing or exacerbating co-existing medical conditions. The program utilizes proprietary analytics, member engagement and patient centric treatment that integrates evidence-based medical and psychosocial interventions along with care coaching in a 52-week outpatient program. Our initial focus was members with substance use disorders. In the second quarter of 2015, we expanded our program into anxiety disorders, and we have plans to expand into other behavioral health conditions for depression. We currently operate our *OnTrak* programs in Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, Oklahoma, West Virginia, and Wisconsin. We provide services to commercial (employer funded), managed Medicare Advantage and managed Medicaid populations.

Recent Developments

On October 16, 2015, we entered into Stock Purchase Agreements (the “Purchase Agreements”) with each of Acuitas Group Holdings, LLC (“Acuitas”), 100% owned by Terren S. Peizer, Chairman and Chief Executive Officer of the Company, Shamus, LLC (“Shamus”), a company owned by David E. Smith, a member of the Company’s board of directors, and Steve Gorlin, a member of the Company’s board of directors (the “Investors”), pursuant to which we received gross proceeds of \$2.0 million for the sale of approximately 6.7 million shares of our common stock, at a purchase price of \$0.30 per share.

In addition, we and Acuitas entered into an amendment to the 12% Original Issue Discount Convertible Debenture (the “Convertible Debenture”) dated July 30, 2015 which extended the maturity date of the Convertible Debenture from January 18, 2016 to January 18, 2017 and extended the date by which we must consummate a qualified public offering from December 31, 2015 to June 30, 2016.

Operations

In the third quarter of 2015, we operated our *OnTrak* programs in Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, Oklahoma, West Virginia and Wisconsin. During the third quarter of 2015, we launched our programs in Illinois and Missouri and signed an agreement with one of our national health plan customers to expand our program to Pennsylvania. In addition, we received approval from one of our national health plan customers to expand our program starting in the fourth quarter of 2015 to its Medicare members in several states under our national contract, which was signed earlier this year. In the third quarter 2015 we enrolled 230% more members in our programs than in the third quarter of 2014. We have generated fees from our launched programs and expect to increase enrollment and fees throughout 2015. However, there can be no assurance that we will generate such fees or that new programs will launch as we expect.

Discontinued Operations

We have discontinued our license and management fees segment. The operations of this segment were shut down effective April 1, 2014 and all of the assets were absorbed by the healthcare services segment.

RESULTS OF OPERATIONS

Table of Summary Consolidated Financial Information

The table below and the discussion that follows summarize our results of consolidated operations for the three and nine months ended September 30, 2015 compared to the three and nine months ended September 30, 2014:

(In thousands, except per share amounts)	Three Months Ended September 30,		Nine Months Ended September 30,	
	2015	2014	2015	2014
Revenues				
Healthcare services revenues	\$ 538	\$ 370	\$ 1,443	\$ 881
Operating expenses				
Cost of healthcare services	720	346	1,655	878
General and administrative	1,968	1,596	7,124	4,642
Depreciation and amortization	30	30	94	82
Total operating expenses	2,718	1,972	8,873	5,602
Loss from operations	(2,180)	(1,602)	(7,430)	(4,721)
Other Income	20	-	41	1,194
Interest expense	(1,209)	(2)	(2,321)	(2,776)
Loss on disposal of intangible assets	(88)	-	(88)	-
Loss on exchange of warrants	-	-	(4,410)	-
Change in fair value of warrant liability	1,007	1,397	10,915	(18,995)
Change in fair value of derivative liability	(5,027)	-	(5,027)	-
Loss from continuing operations before provision for income taxes	(7,477)	(207)	(8,320)	(25,298)
Provision for income taxes	3	3	7	7
Loss from continuing operations	\$ (7,480)	\$ (210)	\$ (8,327)	\$ (25,305)
Loss from discontinued operations, net of income taxes	\$ -	\$ -	\$ -	\$ (213)
Net Loss	\$ (7,480)	\$ (210)	\$ (8,327)	\$ (25,518)
Basic and diluted net loss from continuing operations per share:	\$ (0.16)	\$ (0.01)	\$ (0.23)	\$ (1.17)
Basic weighted number of shares outstanding	47,638	23,513	36,181	21,569
Basic and diluted net loss from discontinued operations per share:	\$ 0.00	\$ 0.00	\$ 0.00	\$ (0.01)
Diluted weighted number of shares outstanding	47,638	23,513	36,181	21,569

Summary of Consolidated Operating Results

Loss from continuing operations before provision for income taxes for the three and nine months ended September 30, 2015 was \$7.5 million and \$8.3 million, compared with a net loss of \$207,000 and \$25.3 million for the same periods in 2014, respectively. The difference primarily relates to the increase in the change in fair value of warrant liability, offset by a loss on exchange of warrants, the change in fair value of derivative liability and an increase in general and administrative expenses for the three and nine months ended September 30, 2015, compared to the same periods in 2014.

Revenues

During the nine months ended September 30, 2015, we have expanded our customer base and health plan populations covered under our programs, which has resulted in a significant increase in the number of patients enrolled in our programs compared with the same period in 2014. For the nine months ended September 30, 2015, enrollment increased by more than 230% over the same period in 2014. Recognized revenue increased by \$168,000 and \$562,000, or 45% and 64%, for the three and nine months ended September 30, 2015, compared with the same periods in 2014, respectively. We reserve a portion, and in some cases all, of the revenue related to these contracts as the revenue is subject to performance guarantees, or in the instance of case rates received upon enrollment and other fees in advance, recognized ratably over the period of enrollment. Deferred revenue increased by \$1.2 million since December 31, 2014, and a \$701,000 increase since June 30, 2015.

Cost of Healthcare Services

Cost of healthcare services consists primarily of salaries related to our care coaches, community care coordinators, healthcare provider claim payments to our network of physicians and psychologists, and fees charged by our third party administrators for processing these claims. The increase of \$374,000 and \$777,000 for the three and nine months ended September 30, 2015, compared with the same periods in 2014, respectively, relates primarily to the increase in the number of members being treated, and the addition of care coaches and clinical care coordinators to our staff to manage the increasing number of enrolled members and the expansion of our program in Kansas to cover high cost members with anxiety disorders.

General and Administrative Expenses

Total general and administrative expense increased by \$372,000 and \$2.5 million for the three and nine months ended September 30, 2015, compared with the same periods in 2014, respectively. The increase was primarily due to an increase in share-based compensation expense related to stock options issued to our board of directors during the first quarter of 2015, investor relations services, and legal services.

Other Income

The decrease of \$1.2 million in other income relates to the 2014 write off of all balances in accounts payable and accrued liabilities related to a contract that was amended and breached in 2010 for which the statute expired in accordance with Section 337 of the California Code of Civil procedures during the second quarter of 2014.

Interest Expense

Interest expense increased by \$1.2 million and decreased by \$455,000, respectively, for the three and nine months ended September 30, 2015 compared with the same periods in 2014, respectively. The increase relates to the issuance of warrants as part of the April 2015 and July 2015 financings during the nine months ended September 30, 2015.

Loss on Exchange of Warrant

The loss of \$4.4 million on the exchange of warrants related to the exchange of 21,277,220 warrants in for 21,277,220 shares of common stock in May 2015 for the nine months ended September 30, 2015.

Change in fair value of warrant liability

We have issued warrants to purchase common stock in November 2010, December 2011, February 2012, April 2015, and July 2015. The warrants are being accounted for as liabilities in accordance with Financial Accounting Standards Board (“FASB”) accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

The decrease in the change in fair value for the warrants was \$390,000 for the three months ended September 30, 2015 and 2014, and an increase of \$29.9 million for the nine months ended September 30, 2015 compared with the same period in 2014.

We will continue to mark-to-market the warrants to market value each quarter-end until they are completely settled.

Change in fair value of derivative liability

The change in fair value of derivative liabilities was \$5.0 million for the three and nine months ended September 30, 2015 compared with the same period in 2014. The derivative liability was the result of the issuance of the July 2015 Convertible Debenture.

We will continue to mark-to-market the derivative liability to market value each quarter-end until they are completely settled.

Depreciation and Amortization

Depreciation and amortization was immaterial for the three and nine months ended September 30, 2015 and 2014, respectively.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity and Going Concern

As of November 12, 2015, we had a balance of approximately \$1.3 million cash on hand. We had working capital deficit of approximately \$11.3 million at September 30, 2015. We have incurred significant operating losses and negative operating cash flows since our inception. We could continue to incur negative cash flows and operating losses for the next twelve months. Our current cash burn rate is approximately \$450,000 per month, excluding non-current accrued liability payments. We expect our current cash resources to cover expenses through the first quarter of 2016; however delays in cash collections, revenue, or unforeseen expenditures could impact this estimate. We are in need of additional capital, however, there is no assurance that additional capital can be timely raised in an amount which is sufficient for us or on terms favorable to us and our stockholders, if at all. If we do not obtain additional capital, there is a significant doubt as to whether we can continue to operate as a going concern and we will need to curtail or cease operations or seek bankruptcy relief. If we discontinue operations, we may not have sufficient funds to pay any amounts to our stockholders.

On October 16, 2015, we entered into the Purchase Agreements with each of Acuitas, Shamus, and Steve Gorlin, pursuant to which we received gross proceeds of \$2.0 million for the sale of approximately 6.7 million shares of our common stock, at a purchase price of \$0.30 per share.

In addition, we and Acuitas entered into an amendment to the Convertible Debenture which extended the maturity date of the Convertible Debenture from January 18, 2016 to January 18, 2017 and extended the date by which we must consummate a qualified public offering from December 31, 2015 to June 30, 2016.

Our ability to fund our ongoing operations and continue as a going concern is dependent on signing and generating fees from existing and new contracts for our Catasys managed care programs and the success of management's plans to increase revenue and continue to control expenses. We currently operate our *OnTrak* program in Florida, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Missouri, New Jersey, Oklahoma, West Virginia and Wisconsin. During the third quarter of 2015, we launched our programs in Illinois and Missouri and signed an agreement with one of our national health plan customers to expand our program to Pennsylvania. In addition, we received approval from one of our national health plan customers to expand our program starting in the fourth quarter of 2015 to its Medicare members in several states under our national contract, which was signed earlier this year. In the third quarter of 2015 we enrolled 230% more members in our programs than in the third quarter of 2014. We have generated fees from our launched programs and expect to increase enrollment and fees throughout 2015. However, there can be no assurance that we will generate such fees or that new programs will launch as we expect. We are in need of additional capital, however, there is no assurance that additional capital can be timely raised in an amount which is sufficient for us or on terms favorable to us and our stockholders, if at all. If we do not obtain additional capital, there is a significant doubt as to whether we can continue to operate as a going concern and we will need to curtail or cease operations or seek bankruptcy relief. If we discontinue operations, we may not have sufficient funds to pay any amounts to our stockholders.

Cash Flows

We used \$3.9 million of cash for continuing operating activities during the nine months ended September 30, 2015 compared with \$3.4 million in the same period in 2014, respectively. Significant non-cash adjustments to operating activities for the nine months ended September 30, 2015 included share-based compensation expense of \$1.2 million, amortization of debt discount of \$2.2 million, loss on exchange of warrants of \$4.4 million, fair value adjustment on derivative liability of \$5.0 million, offset by a fair value adjustment on warrant liability of \$10.9 million.

Capital expenditures for the nine months ended September 30, 2015 were not material. We anticipate that capital expenditures will increase in the future as we replace our computer systems that are reaching their useful lives, upgrade equipment to support our increased number of enrolled members, and enhance the reliability and security of our systems. These future capital expenditure requirements will depend upon many factors, including obsolescence or failure of our systems, progress with expanding the adoption of our programs, and our marketing efforts, the necessity of, and time and costs involved in obtaining, regulatory approvals, competing technological and market developments, and our ability to establish collaborative arrangements, effective commercialization, marketing activities and other arrangements.

Our net cash provided by financing activities was \$3.5 million for the nine months ended September 30, 2015, compared with net cash provided by financing activities of \$4.1 million for the nine months ended September 30, 2014, respectively. Cash provided by financing activities for the nine months ended September 30, 2015 primarily consisted of the net proceeds from the issuance of our 12% Original Issue Discount Convertible Debenture in July 2015.

As discussed above, we currently expend cash at a rate of approximately \$450,000 per month, excluding non-current accrued liability payments. We also anticipate cash inflow to increase during 2015 as we continue to service our executed contracts and sign new contracts. We expect our current cash resources to cover our operations through the first quarter of 2015; however delays in cash collections, revenue, or unforeseen expenditures could impact this estimate. We are in need of additional capital, however, there is no assurance that additional capital can be timely raised in an amount which is sufficient for us or on terms favorable to us and our stockholders, if at all. If we do not obtain additional capital, there is a significant doubt as to whether we can continue to operate as a going concern and we will need to curtail or cease operations or seek bankruptcy relief. If we discontinue operations, we may not have sufficient funds to pay any amounts to our stockholders.

OFF BALANCE SHEET ARRANGEMENTS

As of September 30, 2015, we had no off-balance sheet arrangements.

CRITICAL ACCOUNTING ESTIMATES

The discussion and analysis of our financial condition and results of operations is based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP"). U.S. GAAP requires management to make estimates, judgments and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities. We base our estimates on experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that may not be readily apparent from other sources. On an on-going basis, we evaluate the appropriateness of our estimates and we maintain a thorough process to review the application of our accounting policies. Our actual results may differ from these estimates.

We consider our critical accounting estimates to be those that (1) involve significant judgments and uncertainties, (2) require estimates that are more difficult for management to determine, and (3) may produce materially different results when using different assumptions. We have discussed these critical accounting estimates, the basis for their underlying assumptions and estimates and the nature of our related disclosures herein with the audit committee of our Board of Directors. We believe our accounting policies related to the fair value of warrants, fair value of derivative liabilities, share-based compensation expense, and the impairment assessment for intangible assets, involve our most significant judgments and estimates that are material to our consolidated financial statements. They are discussed further below.

Warrant Liabilities

We have issued warrants to purchase common stock in November 2010, December 2011, February 2012, April 2015, and July 2015. The warrants are being accounted for as liabilities in accordance with FASB accounting rules, due to anti-dilution provisions in some warrants that protect the holders from declines in our stock price and a requirement to deliver registered shares upon exercise of the warrants, which is considered outside our control. The warrants are marked-to-market each reporting period, using the Black-Scholes pricing model, until they are completely settled or expire.

In May 2015, we entered into Warrant Exchange Agreements whereby 21,277,220 warrants, at an exercise price of \$0.58 per shares, issued by the Company between December 2011 and May 2014, were exchanged for 21,277,220 shares of common stock. The principle purpose of the warrant exchange was to increase stockholders' equity by eliminating a liability associated with these warrants.

For the three and nine months ended September 30, 2015 and 2014, we recognized a gain of \$1.0 million and \$10.9 million, respectively, compared with a gain of \$1.4 million and a loss of \$19.0 million for the same periods in 2014, respectively, related to the revaluation of our warrant liabilities.

We will continue to mark the warrants to market value each reporting period, using the Black-Scholes pricing model until they are completely settled or expire.

Derivative Liabilities

In July 2015, we entered into the July 2015 Convertible Debenture. The derivative liability associated with the July 2015 Convertible Debenture was calculated using the Black-Scholes model based upon the following assumptions:

	Sept 30, 2015
Expected volatility	146.52%
Risk-free interest rate	0.10%
Weighted average expected lives in years	0.30
Expected dividend	0%

The expected volatility assumption for the nine months ended September 30, 2015 was based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. The weighted average expected lives in years for 2015 reflect the application of the simplified method set out in Security and Exchange Commission (SEC) Staff Accounting Bulletin (SAB) 107 (and as amended by SAB 110), which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches. We use historical data to estimate the rate of forfeitures assumption for awards granted to employees.

For the three and nine months ended September 30, 2015 and 2014, we recognized a loss of \$5.0 million related to the revaluation of our derivative liability.

Share-based compensation expense

We account for the issuance of stock, stock options, and warrants for services from non-employees based on an estimate of the fair value of options and warrants issued using the Black-Scholes pricing model. This model's calculations include the exercise price, the market price of shares on grant date, weighted average assumptions for risk-free interest rates, expected life of the option or warrant, expected volatility of our stock and expected dividend yield.

The amounts recorded in the financial statements for share-based compensation expense could vary significantly if we were to use different assumptions. For example, the assumptions we have made for the expected volatility of our stock price have been based on the historical volatility of our stock, measured over a period generally commensurate with the expected term. If we were to use a different volatility than the actual volatility of our stock price, there may be a significant variance in the amounts of share-based compensation expense from the amounts reported. The weighted average expected option term for the nine months ended September 30, 2015 and 2014, reflects the application of the simplified method set out in SEC Staff Accounting Bulletin No. 107, which defines the life as the average of the contractual term of the options and the weighted average vesting period for all option tranches.

From time to time, we retain terminated employees as part-time consultants upon their resignation from the Company. Because the employees continue to provide services to us, their options continue to vest in accordance with the original terms. Due to the change in classification of the option awards, the options are considered modified at the date of termination. The modifications are treated as exchanges of the original awards in return for the issuance of new awards. At the date of termination, the unvested options are no longer accounted for as employee awards and are accounted for as new non-employee awards. The accounting for the portion of the total grants that have already vested and have been previously expensed as equity awards is not changed. There were no employees moved to consulting status for the three and nine months ended September 30, 2015 and 2014.

Impairment of Intangible Assets

We have capitalized significant costs for acquiring patents and other intellectual property directly related to our products and services. We review our intangible assets for impairment whenever events or circumstances indicate that the carrying amount of these assets may not be recoverable. In reviewing for impairment, we compare the carrying value of such assets to the estimated undiscounted future cash flows expected from the use of the assets and/or their eventual disposition. If the estimated undiscounted future cash flows are less than their carrying amount, we record an impairment loss to recognize a loss for the difference between the assets' fair value and their carrying value. Since we have not recognized significant revenue to date, our estimates of future revenue may not be realized and the net realizable value of our capitalized costs of intellectual property or other intangible assets may become impaired.

During the three and nine months ended September 30, 2015, we did not acquire any new intangible assets and at September 30, 2015, we determined that the intangible assets had no value and were written off in full.

RECENT ACCOUNTING PRONOUNCEMENTS

In February 2015, the FASB issued Accounting Standards Update ("ASU") 2015-02, *Consolidation (Topic 810): Amendments to the Consolidation Analysis* ("ASU 2015-02"). ASU 2015-02 modifies existing consolidation guidance for reporting organizations that are required to evaluate whether they should consolidate certain legal entities. ASU 2015-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2015, and requires either a retrospective or a modified retrospective approach to adoptions. Early adoption is permitted. We are currently evaluating the potential impact of this standard on our consolidated financial statements, as well as the available transition methods.

In August 2014, the FASB issued FASB ASU 2014-15, *Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern*, (“ASU 2014-15”). ASU 2014-15 changes to the disclosure of uncertainties about an entity’s ability to continue as a going concern. Under U.S. GAAP, continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity’s liquidation becomes imminent. Even if an entity’s liquidation is not imminent, there may be conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern. Because there is no guidance in U.S. GAAP about management’s responsibility to evaluate whether there is substantial doubt about an entity’s ability to continue as a going concern or to provide related note disclosures, there is diversity in practice whether, when, and how an entity discloses the relevant conditions and events in its financial statements. As a result, these changes require an entity’s management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that financial statements are issued. Substantial doubt is defined as an indication that it is probable that an entity will be unable to meet its obligations as they become due within one year after the date that financial statements are issued. If management has concluded that substantial doubt exists, then the following disclosures should be made in the financial statements: (i) principal conditions or events that raised the substantial doubt, (ii) management’s evaluation of the significance of those conditions or events in relation to the entity’s ability to meet its obligations, (iii) management’s plans that alleviated the initial substantial doubt or, if substantial doubt was not alleviated, management’s plans that are intended to at least mitigate the conditions or events that raise substantial doubt, and (iv) if the latter in (iii) is disclosed, an explicit statement that there is substantial doubt about the entity’s ability to continue as a going concern. ASU 2014-15 is effective for periods beginning after December 15, 2016. The adoption of ASU 2013-15 will not have a material effect on our consolidated financial position or results of operations.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Not applicable.

Item 4. Controls and Procedures

Disclosure Controls

We have evaluated, with the participation of our principal executive officer and our principal financial officer, the effectiveness of our disclosure controls and procedures (as defined in the Exchange Act Rules 13a-15(e) and 15d-15(e)) as of September 30, 2015. Based on this evaluation, our principal executive officer and our principal financial officer have concluded that as of September 30, 2015, our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms, and is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the three months ended September 30, 2015, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

There have been no material changes in our risk factors from those disclosed in our most recent Annual Report on Form 10-K.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

None.

Item 3. Defaults Upon Senior Securities

None.

Item 4. Mine Safety Disclosures.

Not applicable.

Item 5. Other Information

None.

Item 6. Exhibits

- Exhibit 4.1 Form of 12% Original Issue Discount Convertible Debenture Due January 18, 2016 (incorporated by reference to Exhibit 4.1 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on July 31, 2015).
- Exhibit 4.2 Form of Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on July 31, 2015).
- Exhibit 4.3 Form of 8% Promissory Note, dated July 22, 2015, between Catasys, Inc. and Crede CG III, Ltd. (incorporated by reference to Exhibit 4.1 of Catasys Inc.'s Form 8-K filed with the Securities and Exchange Commission on July 24, 2015).
- Exhibit 10.1 Form of Stock Purchase Agreement, dated October 16, 2015, by and between Catasys, Inc. and each purchaser identified on the signature pages thereto (incorporated by reference to Exhibit 10.1 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on October 16, 2015).
- Exhibit 10.2 Amendment to 12% Original Issue Discount Convertible Debenture, by and between Catasys, Inc. and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.2 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on October 16, 2015).
- Exhibit 10.3 Stock Purchase Agreement, dated September 17, 2015, by and between Catasys, Inc. and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.1 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on September 18, 2015).
- Exhibit 10.4 Form of Securities Purchase Agreement, dated July 30, 2015, by and between Catasys, Inc. and Acuitas Group Holdings, LLC (incorporated by reference to Exhibit 10.1 of Catasys, Inc.'s Form 8-K filed with the Securities and Exchange Commission on July 31, 2015).
- Exhibit 31.1* Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- Exhibit 31.2* Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

Exhibit 32.1** Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
Exhibit 32.2** Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS* XBRL Instance
101.SCH* XBRL Taxonomy Extension Schema
101.CAL* XBRL Taxonomy Extension Calculation
101.DEF* XBRL Taxonomy Extension Definition
101.LAB* XBRL Taxonomy Extension Labels
101.PRE* XBRL Taxonomy Extension Presentation

* filed herewith.

** furnished herewith.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

CATASYS, INC.

Date: November 13, 2015

By: /s/ TERREN S. PEIZER
Terren S. Peizer
Chief Executive Officer
(Principal Executive Officer)

Date: November 13, 2015

By: /s/ SUSAN ETZEL
Susan Etzel
Chief Financial Officer
(Principal Financial and Accounting Officer)

Exhibit 31.1

CERTIFICATION

I, Terren S. Peizer, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2015

/s/ TERREN S. PEIZER
Terren S. Peizer
Chief Executive Officer
(Principal Executive Officer)

Exhibit 31.2

CERTIFICATION

I, Susan Etzel, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Catasys, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures as of the end of the period covered by this report based on such evaluation; and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
 - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: November 13, 2015

/s/ SUSAN ETZEL

Susan Etzel

Chief Financial Officer

(Principal Financial and Accounting Officer)

Exhibit 32.1

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the "Company") for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Terren S. Peizer, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ TERREN S. PEIZER

Terren S. Peizer

Chief Executive Officer

(Principal Executive Officer)

November 13, 2015

Date

Exhibit 32.2

**CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

In connection with the Quarterly Report on Form 10-Q of Catasys, Inc. (the "Company") for the quarter ended September 30, 2015, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Susan Etzel, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:

- (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m(a) or 78o(d)); and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

/s/ SUSAN ETZEL

Susan Etzel

Chief Financial Officer

(Principal Financial and Accounting Officer)

November 13, 2015

Date